$0.6
3.33%
Downside
Day's Volatility :9.94%
Upside
6.83%
16.58%
Downside
52 Weeks Volatility :92.19%
Upside
90.64%
Period | Bionomics Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -16.2% | 0.0% |
6 Months | -49.15% | 0.0% |
1 Year | -67.49% | 0.0% |
3 Years | -95.96% | -22.3% |
Market Capitalization | 7.9M |
Book Value | $2.72 |
Earnings Per Share (EPS) | -2.05 |
Wall Street Target Price | 6.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -9466.24% |
Return On Assets TTM | -35.13% |
Return On Equity TTM | -80.8% |
Revenue TTM | 662.0K |
Revenue Per Share TTM | 0.07 |
Quarterly Revenue Growth YOY | 9.3% |
Gross Profit TTM | -19.0M |
EBITDA | -25.7M |
Diluted Eps TTM | -2.05 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 900.0%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 6.6M | ↓ 57.7% |
Net Income | -13.9M | ↑ 257.91% |
Net Profit Margin | -211.13% | ↓ 186.18% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 3.6M | ↓ 41.21% |
Net Income | -5.1M | ↓ 60.66% |
Net Profit Margin | -141.25% | ↑ 69.88% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.4M | ↓ 60.06% |
Net Income | -2.8M | ↓ 45.01% |
Net Profit Margin | -194.47% | ↓ 53.22% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 531.5K | ↓ 66.3% |
Net Income | -5.0M | ↑ 62.39% |
Net Profit Margin | -937.11% | ↓ 742.64% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.9M | ↑ 500.75% |
Net Income | -10.6M | ↑ 130.36% |
Net Profit Margin | -359.34% | ↑ 577.77% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 290.7K | ↓ 89.65% |
Net Income | -14.2M | ↑ 41.19% |
Net Profit Margin | -4.9K% | ↓ 4543.17% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.7M | ↑ 6065.76% |
Net Income | -4.0M | ↑ 10.49% |
Net Profit Margin | -147.91% | ↑ 8105.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 61.0K | ↓ 97.78% |
Net Income | -7.4M | ↑ 83.57% |
Net Profit Margin | -12.2K% | ↓ 12058.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 172.6K | ↑ 185.87% |
Net Income | -5.2M | ↓ 29.13% |
Net Profit Margin | -3.0K% | ↑ 9180.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.3K | ↓ 81.94% |
Net Income | -3.3M | ↓ 36.83% |
Net Profit Margin | -10.6K% | ↓ 7561.32% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 344.2K | ↑ 637.78% |
Net Income | -10.4M | ↑ 110.87% |
Net Profit Margin | -3.0K% | ↑ 7561.31% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 98.9K | ↓ 71.26% |
Net Income | -10.5M | ↑ 0.56% |
Net Profit Margin | -10.6K% | ↓ 7561.33% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 36.1M | ↓ 25.47% |
Total Liabilities | 26.7M | ↑ 6.2% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 26.2M | ↓ 21.77% |
Total Liabilities | 18.1M | ↓ 26.73% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 16.4M | ↓ 36.87% |
Total Liabilities | 10.4M | ↓ 42.38% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 31.1M | ↑ 71.08% |
Total Liabilities | 3.8M | ↓ 66.75% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 31.7M | ↑ 10.82% |
Total Liabilities | 4.1M | ↑ 15.99% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 19.2M | ↓ 36.48% |
Total Liabilities | 4.4M | ↑ 13.23% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 30.2M | ↓ 30.96% |
Total Liabilities | 3.9M | ↓ 30.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 25.9M | ↓ 14.99% |
Total Liabilities | 3.9M | ↑ 0.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.9M | ↓ 57.41% |
Total Liabilities | 1.4M | ↓ 64.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 16.8M | ↑ 52.97% |
Total Liabilities | 4.2M | ↑ 200.68% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 18.4M | ↑ 14.68% |
Total Liabilities | 4.2M | ↑ 4.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 17.7M | ↓ 7.55% |
Total Liabilities | 4.5M | ↑ 1.95% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.3M | ↑ 1267.92% |
Investing Cash Flow | 60.9K | - |
Financing Cash Flow | 1.5M | ↓ 221.9% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.6M | ↓ 27.74% |
Investing Cash Flow | 137.3K | ↑ 143.28% |
Financing Cash Flow | 2.1M | ↑ 56.71% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.7M | ↓ 64.32% |
Investing Cash Flow | -134.6K | ↓ 198.72% |
Financing Cash Flow | -3.7M | ↓ 275.33% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.8M | ↑ 93.14% |
Investing Cash Flow | -61.3K | ↓ 58.9% |
Financing Cash Flow | 24.1M | ↓ 689.02% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.6M | ↑ 99.24% |
Investing Cash Flow | 437.0K | ↓ 875.13% |
Financing Cash Flow | 13.1M | ↓ 40.93% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.5M | ↓ 5.36% |
Investing Cash Flow | 322.1K | ↓ 22.87% |
Financing Cash Flow | 2.5M | ↓ 80.14% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↑ 13.16% |
Investing Cash Flow | 64.0K | ↑ 2486.63% |
Financing Cash Flow | 1.1M | ↓ 366.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↓ 0.37% |
Investing Cash Flow | 64.5K | ↑ 0.0% |
Financing Cash Flow | 2.7M | ↑ 142.54% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -435.5K | ↓ 89.37% |
Investing Cash Flow | 96.3K | ↑ 50.93% |
Financing Cash Flow | -204.4K | ↓ 107.55% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.1M | ↑ 605.27% |
Investing Cash Flow | 96.9K | ↑ 0.0% |
Financing Cash Flow | 2.4M | ↓ 1263.52% |
Sell
Neutral
Buy
Bionomics Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bionomics Ltd | -0.67% | -49.15% | -67.49% | -95.96% | -95.96% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bionomics Ltd | NA | NA | NA | 0.0 | -0.81 | -0.35 | NA | 2.72 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bionomics Ltd | Buy | $7.9M | -95.96% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Bionomics Ltd
Revenue is down for the last 2 quarters, 344.22K → 98.93K (in $), with an average decrease of 71.3% per quarter
Netprofit is down for the last 3 quarters, -4.93M → -10.47M (in $), with an average decrease of 55.7% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 104.6%
Armistice Capital, LLC
Point72 Asset Management, L.P.
TWO SIGMA SECURITIES, LLC
Lewis Asset Management LLC
Two Sigma Investments LLC
Beacon Pointe Advisors, LLC
bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and alzheimer's disease. our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options. we are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. this portfolio is fed by highly productive drug discovery platforms which includes multicore®, our proprietary chemistry capability. at the core of our business is strategic partnering. we partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. this means we can focus our strengths in innovative drug discovery to extract as many "shots on goal" from our diverse pipeline in the quest to create the world's new blockbuster drugs. we have a passion for
Organization | Bionomics Ltd |
Employees | 0 |
CEO | Dr. Spyridon Papapetropoulos M.D., Ph.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.60
-1.7%
Keyarch Acquisition Corp
$0.60
-1.7%
Connexa Sports Technologies Inc
$0.60
-1.7%
Us Value Etf
$0.60
-1.7%
First Wave Biopharma Inc
$0.60
-1.7%
Global X Msci Next Emerging
$0.60
-1.7%
Fat Projects Acquisition Corp
$0.60
-1.7%
Capital Link Global Fintech
$0.60
-1.7%
Applied Uv Inc
$0.60
-1.7%